Access the full text.
Sign up today, get DeepDyve free for 14 days.
Quasar Group (2007)
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised studyThe Lancet, 370
(2020)
NCCN Guidelines Version 1.2020, Colon Cancer
A. Merlos-Suárez, Francisco Barriga, P. Jung, M. Iglesias, M. Céspedes, D. Rossell, Marta Sevillano, Xavier Hernando-Momblona, Victoria Silva-Diz, P. Muñoz, H. Clevers, E. Sancho, R. Mangues, E. Batlle (2011)
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse.Cell stem cell, 8 5
Bao‐cun Sun, Xiulan Zhao, Shi-wu Zhang, Yi-xin Liu, Lan Wang, Xin Wang (2005)
Sulindac induces apoptosis and protects against colon carcinoma in mice.World journal of gastroenterology, 11 18
Jared Fischer, A. Schepers, A. Schepers, H. Clevers, D. Shibata, R. Liskay (2014)
Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention.Carcinogenesis, 35 1
C. Böckelman, B. Engelmann, T. Kaprio, T. Hansen, B. Glimelius (2015)
Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literatureActa Oncologica, 54
R. Siegel, K. Miller, A. Jemal (2019)
Cancer statistics, 2019CA: A Cancer Journal for Clinicians, 69
W. Schippinger, H. Samonigg, R. Schaberl-Moser, R. Greil, R. Thödtmann, J. Tschmelitsch, M. Jagoditsch, G. Steger, R. Jakesz, F. Herbst, F. Hofbauer, H. Rabl, P. Wohlmuth, M. Gnant, J. Thaler (2007)
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancerBritish Journal of Cancer, 97
Y. Beazer-Barclay, D. Levy, A. Moser, W. Dove, S. Hamilton, B. Vogelstein, K. Kinzler (1996)
Sulindac suppresses tumorigenesis in the Min mouse.Carcinogenesis, 17 8
Manisha Bhutani, A. Pathak, You-Hong Fan, Diane Liu, J. Lee, Hongli Tang, J. Kurie, R. Morice, Edward Kim, Qiang Shen, I. Uray, Yuxin Li, Yun Zhang, Jamal Hill, Xiao-Chun Xu, M. Young, Edward Gunther, Susan Hilsenbeck, N. Colburn, Lewis Chodosh, Tricia Moore, Linda Beltran, Steve Carbajal, Sara Strom, Jeanine Traag, S. Hursting (2008)
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind TrialCancer Prevention Research, 1
C. Matsuda, M. Ishiguro, S. Teramukai, Y. Kajiwara, S. Fujii, Y. Kinugasa, Y. Nakamoto, M. Kotake, Y. Sakamoto, K. Kurachi, A. Maeda, K. Komori, N. Tomita, Y. Shimada, Keiichi Takahashi, K. Kotake, M. Watanabe, H. Mochizuki, Y. Nakagawa, K. Sugihara (2018)
A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.European journal of cancer, 96
Benson AB III
Benson AB III, 2020
D. Axelrod, R. Bravo (2017)
Chemoprevention of colon cancer: advantage of intermittent pulse treatment schedules quantified by computer simulation of human colon crypts, 3
R. Bravo, D. Axelrod (2013)
A calibrated agent-based computer model of stochastic cell dynamics in normal human colon crypts useful for in silico experimentsTheoretical Biology & Medical Modelling, 10
A. Figueredo, M. Charette, J. Maroun, M. Brouwers, L. Zuraw (2004)
Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
J. Keller, G. Offerhaus, M. Polak, Steven Goodman, Marianna Zahurak, L. Hylind, Stanley Hamilton, F. Giardiello (1999)
Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindacGut, 45
Chase Cockrell, G. An (2017)
Sepsis Reconsidered: Identifying novel metrics for behavioral landscape characterization with a high-performance computing implementation of an agent-based modelbioRxiv
A. Baker, B. Cereser, S. Melton, A. Fletcher, M. Rodríguez-Justo, P. Tadrous, A. Humphries, G. Elia, S. McDonald, N. Wright, B. Simons, M. Jansen, T. Graham (2014)
Quantification of Crypt and Stem Cell Evolution in the Normal and Neoplastic Human ColonCell Reports, 8
Chase Cockrell, D. Axelrod (2018)
Optimization of Dose Schedules for Chemotherapy of Early Colon Cancer Determined by High-Performance Computer SimulationsCancer Informatics, 18
P. Lynch (2016)
Chemoprevention of familial adenomatous polyposisFamilial Cancer, 15
G. An (2004)
In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling*Critical Care Medicine, 32
D. Sargent, A. Sobrero, A. Grothey, M. O’connell, M. Buyse, T. André, Yan Zheng, E. Green, R. Labianca, C. O'Callaghan, J. Seitz, G. Francini, D. Haller, G. Yothers, R. Goldberg, A. Gramont (2009)
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 6
T. André, P. Colin, C. Louvet, E. Gamelin, O. Bouché, E. Achille, N. Colbert, C. Boaziz, P. Piedbois, N. Tubiana-Mathieu, A. Boutan-Laroze, M. Flesch, M. Buyse, A. Gramont (2003)
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 15
S. Boolbol, A. Dannenberg, A. Chadburn, C. Martucci, Xiaojun Guo, John Ramonetti, Maria Abreu-Goris, H. Newmark, M. Lipkin, J. Decosse, M. Bertagnolli (1996)
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.Cancer research, 56 11
L. Santana, S. Ganesan, G. Bhanot (2019)
A Quasi Birth-and-Death Model For Tumor RecurrencebioRxiv
S. Dosso, C. Sessa, P. Saletti (2009)
Adjuvant therapy for colon cancer: present and perspectives.Cancer treatment reviews, 35 2
Swati Chandra, Ariel Nymeyer, P. Rice, E. Gerner, J. Barton (2017)
Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse ModelCancer Prevention Research, 10
L. Ritsma, S. Ellenbroek, A. Zomer, H. Snippert, F. Sauvage, B. Simons, H. Clevers, J. Rheenen (2014)
Intestinal crypt homeostasis revealed at single stem cell level by in vivo live-imagingNature, 507
E. Osterman, B. Glimelius (2018)
Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish PopulationDiseases of the Colon & Rectum, 61
D. Axelrod, Sudeepti Vedula, James Obaniyi (2017)
Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation studyCancer Chemotherapy and Pharmacology, 79
C. Moertel, T. Fleming, J. Macdonald, D. Haller, J. Laurie, C. Tangen, J. Ungerleider, W. Emerson, D. Tormey, J. Glick (1995)
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
H. Lee-Six, S. Olafsson, Peter Ellis, Robert Osborne, M. Sanders, L. Moore, N. Georgakopoulos, F. Torrente, A. Noorani, M. Goddard, Philip Robinson, Tim Coorens, L. O’Neill, Christopher Alder, Jingwei Wang, R. Fitzgerald, M. Zilbauer, N. Coleman, K. Saeb‐Parsy, I. Martincorena, P. Campbell, M. Stratton (2018)
The landscape of somatic mutation in normal colorectal epithelial cellsNature, 574
N. Samadder, S. Kuwada, Kenneth Boucher, K. Byrne, P. Kanth, W. Samowitz, David Jones, Sean Tavtigian, M. Westover, Therese Berry, K. Jasperson, L. Pappas, L. Smith, D. Sample, Randall Burt, D. Neklason (2018)
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical TrialJAMA Oncology, 4
PURPOSE: Adjuvant chemotherapy is used after surgery for stages II and III colorectal cancer to reduce recurrence. Nevertheless, recurrence may occur years later with the emergence of initially undetected minimal residual disease (MRD). Attempts to reduce recurrence by increasing the dose intensity and increasing the time of adjuvant therapy have been limited by the adverse effects of the recommended cytotoxic agents. The goals of this study were to suggest an alternative to the recommended cytotoxic agents and to determine optimal adjuvant therapy dose schedules that would reduce the percentage of recurrence at 5 years while retaining colon crypt function. METHODS: A total of 84,400 dose schedules with different duration, interval between doses, and intensity of treatment were simulated with a high-performance computer. Simulated treatments used the drug sulindac, which had previously been used in primary prevention. With appropriate dose schedules, it can induce apoptosis at the crypt lumen surface while retaining crypt function. We used a computer model of cell dynamics in colon crypts that had been calibrated with measurements of human biopsy specimens. Proliferating mutant cells were assumed to emerge from MRD within crypts. Simulated outcomes included the recurrence percentage at 5 years and the retention of crypt function. RESULTS: Optimal dose schedules were determined for adjuvant treatment of MRD that reduced the percentage of recurrence at 5 years of stages I, II, and III colon cancer to zero. CONCLUSION: A new adjuvant therapy for colon cancer based upon optimum dose schedules of intermittent apoptotic treatment may prevent the recurrence of colon cancer from MRD and avoid the adverse effects of cytotoxic treatments.
JCO Clinical Cancer Informatics – Wolters Kluwer Health
Published: Jun 8, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.